Conflict of Interest Disclosures: Dr Barthélemy reported receiving grants from The Coins For Alzheimer's Research Trust, Tracy Family SILQ Center Pilot, and Knight ADRC Developmental Projects and having the following patents: methods to detect novel tau species in cerebrospinal fluid, methods to track tau neuropathology in Alzheimer’s disease and other tauopathies, and methods for diagnosing and treating based on site-specific tau phosphorylation, all licensed to C2N Diagnostics. Dr Schindler reported receiving personal fees from Eisai outside the submitted work. Dr Palmqvist reported receiving research support (for the institution) from Ki:elements, Alzheimer’s Drug Discovery Foundation, and Avid and consultancy/speaker fees from Bioartic, Biogen, Esai, Lilly, and Roche. Dr Braunstein reported being employed by C2N Diagnostics. Dr Ovod reported having a patent for plasma-based methods for detecting central nervous system amyloid deposition licensed to C2N Diagnostics. Dr Bollinger reported having a pending patent for plasma-based methods for detecting central nervous system amyloid deposition licensed to C2N Diagnostics. Dr Raji reported receiving grants from National Institutes of Health/National Institute on Aging and the Department of Defence and personal/consulting fees from CoreTechs.ai, Pacific Neuroscience Institute, Voxelwise, Eli Lilly, and Neurevolution outside the submitted work. Dr Morris reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Holtzman reported being cofounder of, receiving equity from, and serving on the scientific advisory board of C2N Diagnostics; receiving advisory board fees from Genentech and Cajal Neurosciences; and having a patent for methods for measuring the metabolism of neutrally derived biomolecules in vivo with royalties paid from C2N Diagnostics. Dr Blennow reported serving as a consultant and on advisory boards for AbbVie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; serving on data monitoring committees for Julius Clinical and Novartis; giving lectures, producing educational materials, and participating in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and being a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the submitted work. Dr Bateman reported receiving research funding from the National Institutes of Health, Alzheimer’s Association, BrightFocus Foundation, Rainwater Foundation, Association for Frontotemporal Degeneration FTD Biomarkers Initiative, Tau Consortium, Novartis, Centene Corporation, Association for Frontotemporal Degeneration, the Cure Alzheimer's Fund, Coins for Alzheimer’s Research Trust Fund, The Foundation for Barnes-Jewish Hospital, Good Ventures Foundation, DIAN-TU Pharma Consortium, Centene Corporation, Tau SILK Consortium (AbbVie, Biogen, Eli Lilly and Company and an anonymous organization), the NfL Consortium (AbbVie, Biogen, Bristol Meyers Squibb, Hoffman La Roche, and an anonymous organization); speaker/consultant/advisory board honoraria from Eisai, F. Hoffman-LaRoche, Janssen, Biogen; paid travel expenses from Korean Dementia Association, American Neurological Association, Fondazione Prada, Weill Cornell Medical College, Harvard University, CTAD, FBRI, Beeson Foundation, Adler, Alzheimer’s Association Roundtable, Duke Margolis Roundtable, Bright Focus Foundation, Tau Consortium Investigator’s, NAPA Advisory Council on Alzheimer’s Research; serving as principal investigator of the DIAN-TU (which is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization and the DIAN-TU Pharma Consortium [active: Biogen, Eisai, Eli Lilly and Company/Avid Radiopharmaceuticals, F. Hoffman-La Roche/Genentech, and Janssen. Previous: AbbVie, Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi, and United Neuroscience]). The DIAN-TU-001 Clinical Trial is supported by Pharmaceutical Partners Eli Lilly and Company, F. Hoffman-La Roche and Janssen, the Alzheimer’s Association, National Institutes of Health grants U01AG042791, U01AG42791-S1 (FNIH and Accelerating Medicines Partnership), R01AG046179, R56AG053267, R01AG053267, U01AG059798, R01AG068319, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. In-kind support has been received from CogState, Cerveau, Signant Health and Eisai Corporation; and being a cofounder of C2N Diagnostics and receiving income from C2N Diagnostics for serving on the scientific advisory board. Washington University has equity ownership interest in C2N Diagnostics. Dr Hansson reported receiving advisory board fees from Lilly, Roche, Eisai, and Novo Nordisk outside the submitted work. No other disclosures were reported.
PubMed
